Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0W2CX
|
||||
| Former ID |
DNCL001593
|
||||
| Drug Name |
CG-100649
|
||||
| Drug Type |
Small molecular drug
|
||||
| Company |
CG Pharmaceuticals
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C18H16FNO4S
|
||||
| InChI |
InChI=1S/C18H16FNO4S/c1-18(2)17(21)15(12-4-3-5-13(19)10-12)16(24-18)11-6-8-14(9-7-11)25(20,22)23/h3-10H,1-2H3,(H2,20,22,23)
|
||||
| InChIKey |
IJWPAFMIFNSIGD-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | Prostaglandin G/H synthase 2 | Target Info | Inhibitor | [532911] | |
| Carbonic anhydrase I | Target Info | Inhibitor | [533275] | ||
| Carbonic anhydrase II | Target Info | Inhibitor | [533275] | ||
| KEGG Pathway | Arachidonic acid metabolism | ||||
| Metabolic pathways | |||||
| NF-kappa B signaling pathway | |||||
| VEGF signaling pathway | |||||
| TNF signaling pathway | |||||
| Retrograde endocannabinoid signaling | |||||
| Serotonergic synapse | |||||
| Ovarian steroidogenesis | |||||
| Oxytocin signaling pathway | |||||
| Regulation of lipolysis in adipocytes | |||||
| Leishmaniasis | |||||
| Pathways in cancer | |||||
| Chemical carcinogenesis | |||||
| MicroRNAs in cancer | |||||
| Small cell lung cancerhsa00910:Nitrogen metabolismhsa00910:Nitrogen metabolism | |||||
| Proximal tubule bicarbonate reclamation | |||||
| Collecting duct acid secretion | |||||
| Gastric acid secretion | |||||
| Pancreatic secretion | |||||
| Bile secretion | |||||
| PathWhiz Pathway | Arachidonic Acid MetabolismPW000565:Gastric Acid Production | ||||
| WikiPathways | Prostaglandin Synthesis and Regulation | ||||
| Arachidonic acid metabolism | |||||
| Aryl Hydrocarbon Receptor | |||||
| Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis | |||||
| Spinal Cord Injury | |||||
| Integrated Pancreatic Cancer Pathway | |||||
| Eicosanoid Synthesis | |||||
| Selenium Micronutrient NetworkWP2770:Reversible Hydration of Carbon Dioxide | |||||
| Uptake of Carbon Dioxide and Release of Oxygen by Erythrocytes | |||||
| Uptake of Oxygen and Release of Carbon Dioxide by ErythrocytesWP2770:Reversible Hydration of Carbon Dioxide | |||||
| Uptake of Oxygen and Release of Carbon Dioxide by Erythrocytes | |||||
| References | |||||
| Ref 524183 | ClinicalTrials.gov (NCT01765296) Phase III Study of CG100649 in Osteoarthritis Patients. U.S. National Institutes of Health. | ||||
| Ref 543067 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8316). | ||||
| Ref 532911 | Pharmacokinetic, pharmacodynamic, and safety/tolerability profiles of CG100649, a novel COX-2 inhibitor: results of a phase i, randomized, multiple-dose study in healthy Korean men and women. Clin Ther. 2015 Jan 1;37(1):197-210. | ||||
| Ref 533275 | Understanding the Dual Inhibition of COX-2 and Carbonic Anhydrase-II by Celecoxib and CG100649 Using Density Functional Theory Calculations and other Molecular Modelling Approaches. Protein Pept Lett. 2015;22(10):903-12. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.